Deploy the latest solutions to maximise the value of your study data and deliver real-time visibility on your study progress.
About Avance Clinical
Avance Clinical is an Australian owned Contract Research Organisation (CRO) that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years. Avance Clinical specialises in supporting biotech companies with their early phase clinical trials leveraging the world-class early phase clinical trials ecosystem in Australia.
Avance Clinical has a global reputation for outstanding service to our biotech clients in the United States, United Kingdom, Japan, China, South Korea, Taiwan, France and Germany.
As a leading Australian CRO, with extensive experience across all phases of clinical research, complemented with our full suite of in-house clinical research services, we can ensure your trials are delivered on time and on budget as a certified contract research organisation.
“We aim to give clients unparalleled service to optimise the timely and cost effective completion of projects. It’s as simple as that”
Chief Executive Officer
“It has been a great pleasure working with you on this project. Your flexibility, pragmatic approaches and focus on the work has been exceptional. I am looking forward to have the next compound entering the clinic with you.”
Head of Drug Discovery Pharmaxis Ltd
“Working with the Avance Team has helped us to develop and complete high quality and compliant clinical studies. I especially appreciate their penchant for communication, quality and pragmatism.”
Australia’s CRO for biotechs, Avance Clinical, deep dives into the patient recruitment landscape identifying the mechanisms and processes that deliver exceptional patient recruitment for early phase trials in Australia.
The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony.
Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in Australia and Central/Eastern Europe, respectively, are successfully collaborating on a scalable clinical solution for biotechs.
The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that client Atossa Therapeutics has announced a positive interim safety assessment from the second cohort of healthy participants in the Phase 1 clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray.
Avance Clinical has formed a dedicated scientific and regulatory affairs service, ClinicReady by Avance Clinical, in response to increased demand from biotechs for preclinical study management and scientific and regulatory advice to take their products to first-in-human trials.
The highly regarded Avance Clinical scientific and regulatory team, which has been advising biotech clients on their drug development for more than 20 years, is now a dedicated ClinicReady service under the Avance Clinical banner.
The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has expanded its eClinical solutions offering, with advanced digital clinical tools for enhanced patient engagement, visibility, data capture, and analysis.
Avance Clinical made the announcement at BioPharm America (September 21-24, 2020)
The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to announce the appointment of Jorgen Mould PhD, BSc (Hons) as Scientific Affairs Specialist
Jorgen has over 23 years of experience in medical research and drug development.
With a passion for developing new treatments for human diseases, Jorgen has worked in positions that span the full spectrum of a drug lifecycle from bench side discovery to post market approval.
The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that its client Immunic Therapeutics has announced dosing of the first healthy volunteer in the company’s phase 1 clinical program of IMU-856, an novel treatment for patients suffering from gastrointestinal diseases, including diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn’s disease.
The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that Atossa Therapeutics have enrolled and dosed the first cohort of healthy participants in the Phase 1 clinical study using its proprietary drug candidate AT-301, being administered by nasal spray.